#weightlossdrugs
Eli Lilly becomes first health-care firm to briefly reach $1 trillion market value
Eli Lilly reached a historic milestone on Friday when it briefly surpassed a $1 trillion market capitalization, becoming the first health-care company in the world to enter a territory long dominated by technology giants. The company’s stock hovered near $1,048 per share during morning trading, touching the trillion-dollar threshold before pulling back slightly. It is only the second nontechnology business in the United States to reach this valuation, following Berkshire Hathaway’s climb
Eli Lilly becomes first health-care firm to briefly reach $1 trillion market value
Eli Lilly reached a historic milestone on Friday when it briefly surpassed a $1 trillion market capitalization, becoming the first health-care company in the world to enter a territory long dominated by technology giants. The company’s stock hovered near $1,048 per share during morning trading, touching the trillion-dollar threshold before pulling back slightly. It is only the second nontechnology business in the United States to reach this valuation, following Berkshire Hathaway’s climb
Novo Nordisk cuts Ozempic price to $499 for uninsured diabetes patients
Novo Nordisk has announced a major price cut for its popular diabetes medication Ozempic, offering the drug for just $499 per month for patients in the United States who are uninsured or paying out-of-pocket. This move represents a significant reduction from the previous list price of nearly $1,350, and it is aimed at improving access for patients who otherwise struggle to afford the medication. The drug will now be available at the lower price through the comp
Novo Nordisk cuts Ozempic price to $499 for uninsured diabetes patients
Novo Nordisk has announced a major price cut for its popular diabetes medication Ozempic, offering the drug for just $499 per month for patients in the United States who are uninsured or paying out-of-pocket. This move represents a significant reduction from the previous list price of nearly $1,350, and it is aimed at improving access for patients who otherwise struggle to afford the medication. The drug will now be available at the lower price through the comp
Are Weight Loss Drugs Really the Solution? Understanding GLP-1 and Its Impact on Obesity
The rise of anti-obesity drugs, especially GLP-1 medications like Wegovy and Mounjaro, has sparked a debate about their role in weight loss. As India’s anti-obesity drug market is expected to grow rapidly, with projections reaching ₹25,000 crore by 2030, these drugs have become a common solution for people struggling with obesity. But the question remains: are they necessary for everyone, or are they a quick fix for deeper health issues?
Are Weight Loss Drugs Really the Solution? Understanding GLP-1 and Its Impact on Obesity
The rise of anti-obesity drugs, especially GLP-1 medications like Wegovy and Mounjaro, has sparked a debate about their role in weight loss. As India’s anti-obesity drug market is expected to grow rapidly, with projections reaching ₹25,000 crore by 2030, these drugs have become a common solution for people struggling with obesity. But the question remains: are they necessary for everyone, or are they a quick fix for deeper health issues?
New Study Links Weight-Loss Drugs to Serious Eye Conditions and Vision Loss
Weight-loss drugs, particularly GLP-1 medications like semaglutide and tirzepatide, are gaining traction among diabetes and obesity patients in India. While these drugs offer benefits like controlling blood sugar and aiding in weight loss, recent studies have uncovered potential eye health risks. A new study published in JAMA has linked these medications to rare but serious eye conditions, with a focus on optic nerve disorders such as non-arteritic anterior is
New Study Links Weight-Loss Drugs to Serious Eye Conditions and Vision Loss
Weight-loss drugs, particularly GLP-1 medications like semaglutide and tirzepatide, are gaining traction among diabetes and obesity patients in India. While these drugs offer benefits like controlling blood sugar and aiding in weight loss, recent studies have uncovered potential eye health risks. A new study published in JAMA has linked these medications to rare but serious eye conditions, with a focus on optic nerve disorders such as non-arteritic anterior is
Medi-Cal May Drop Ozempic, Wegovy Coverage by 2026
Under a new cost-cutting proposal by Governor Gavin Newsom, California may soon eliminate Medi-Cal coverage for popular weight loss drugs Ozempic and Wegovy, sparking concern among healthcare advocates and low-income patients. The move, which aims to address a $12 billion state budget deficit, could take effect on January 1, 2026, and would save the state an estimated $85 million in 2025–26 and up to $680 million by 2028–29, according to Newsom's office. Ozempic and
Medi-Cal May Drop Ozempic, Wegovy Coverage by 2026
Under a new cost-cutting proposal by Governor Gavin Newsom, California may soon eliminate Medi-Cal coverage for popular weight loss drugs Ozempic and Wegovy, sparking concern among healthcare advocates and low-income patients. The move, which aims to address a $12 billion state budget deficit, could take effect on January 1, 2026, and would save the state an estimated $85 million in 2025–26 and up to $680 million by 2028–29, according to Newsom's office. Ozempic and









